RESULTS AT A GLANCE

The efficacy and safety of XELJANZ^® (tofacitinib) were tested in 2 clinical studies that involved adult patients with active psoriatic arthritis. In these studies, patients took XELJANZ 5 mg twice a day in addition to a nonbiologic DMARD such as methotrexate. XELJANZ reduced joint pain and swelling in as early as 2 weeks. For some, it took 3 to 6 months.* Individual results may vary.

XELJANZ may cause serious side effects. Learn more about the Most Important Risk Information you should know about XELJANZ.

^*Results were seen for patients taking XELJANZ in combination with a nonbiologic disease-modifying antirheumatic drug (DMARD).